Page 74 - MEMORIA ANUAL 2019 SEHH-FEHH
P. 74
Programa EsPañol dE TraTamiEnTos En HEmaTología (PETHEma)
MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Tormo M, Cervera M, Martínez-Carballeira D, Novo A, González-Campos J, Soria B, Bermúdez A, López Martínez A, Mercadal S, Fernández-Martín R, Coll R, Serrano J, Amigo ML, Martínez-Sánchez P, Bergua JM, Serrano-Maestro A, Giménez Conca A, Barrena S, Granada I, Feliú E, Orfao A. Post-Remission Treatment with Chemo- therapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Dis- ease (MRD). Final Results of the Pethema ALL-HR-11 Trial. 61st Annual Meeting of the American Society of Hematology (ASH). Orlando, FL, Dec 07-10, 2019. Blood. 2019;134(Supplement_1):826. https://doi.org/10.1182/blood-2019-123613.
• Botta C, Pérez Ruiz C, Goicoechea I, Puig N, Cedena MT, Cordón L, Zabaleta A, Burgos L, Maia C, Rodríguez S, Rodríguez I, Sarvide S, Alignani D, Vilas-Zornoza A, Lorenzo-Vivas E, Rosinol Dachs L, Oriol A, Blanchard MJ, Ríos, Sureda A, Martínez R, Martín J, Bargay J, De La Rubia J, Rossi M, Tagliaferri P, Tassone P, Gentile M, Merino J, Prosper F, Orfao A, Mateos MV, Lahuerta JJ, Bladé J, San-Miguel J, Paiva B. Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microen- vironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reac- tive Lymphocytes. 61st Annual Meeting of the ASH. Orlando, FL, Dec 07-10, 2019. Blood. 2019;134(Supplement_1):506. https://doi.org/10.1182/blood-2019-123974.
• Mateos MV, Martínez-López J, Rodríguez Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Paiva B, Ríos Tamayo R, Rosinol Dachs L, Álvarez MA, Cala- sanz MJ, Bargay J, González AP, Alegre Amor A, Escalante F, Íñigo B, Puig N, De La Rubia J, Teruel AI, Cedena Romero MT, De Arriba F, Palomera L, Hernández MT, Ló- pez Jiménez J, Martín J, García Mateo A, Ocio EM, Bladé J, Lahuerta JJ, San-Miguel J. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. 61st Annual Meeting of the ASH. Orlando, Dec 7-10, 2019. Blood. 2019;134(Supplement_1):781. https:// doi.org/10.1182/blood-2019-125204.
• Puig N, Hernández MT, Rosinol Dachs L, González García E, De Arriba F, Oriol A, González-Calle V, Escalante F, De La Rubia J, Gironella Meda M, Ríos Tamayo R, Gar- cía Sánchez RB, Arguiñano Pérez JM, Alegre Amor A, Martín J, Gutiérrez NC, Cala- sanz MJ, Martín-Ramos ML, Couto Caro MC, Casanova M, Arnao M, Pérez Persona E, Garzón López S, González MS, Martín Sánchez G, Rossi AC, Coleman M, Encinas C, Vale López AM, Teruel AI, Paiva B, Cedena Romero MT, San-Miguel J, Lahuer- ta JJ, Bladé J, Niesvizky R, Mateos MV. Randomized Trial of Lenalidomide and
74
